JPMorgan Chase & Co. Issues Positive Forecast for Teva Pharmaceutical Industries (NYSE:TEVA) Stock Price

Teva Pharmaceutical Industries (NYSE:TEVA) had its price target raised by JPMorgan Chase & Co. from $35.00 to $40.00 in a research note released on Thursday,Benzinga reports. They currently have an overweight rating on the stock.

Other analysts have also recently issued reports about the stock. Wall Street Zen upgraded shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a report on Saturday, January 31st. UBS Group boosted their price objective on shares of Teva Pharmaceutical Industries from $36.00 to $42.00 and gave the stock a “buy” rating in a report on Thursday. The Goldman Sachs Group boosted their price objective on shares of Teva Pharmaceutical Industries from $36.00 to $45.00 and gave the stock a “buy” rating in a report on Monday, February 9th. Jefferies Financial Group boosted their price objective on shares of Teva Pharmaceutical Industries from $29.00 to $40.00 and gave the stock a “buy” rating in a report on Tuesday, January 6th. Finally, Piper Sandler reiterated an “overweight” rating and issued a $42.00 price objective (up from $41.00) on shares of Teva Pharmaceutical Industries in a report on Thursday. Nine investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $41.56.

Teva Pharmaceutical Industries Stock Down 1.0%

Shares of NYSE TEVA opened at $35.03 on Thursday. Teva Pharmaceutical Industries has a 52-week low of $14.99 and a 52-week high of $37.35. The firm has a fifty day moving average of $31.15 and a 200-day moving average of $29.33. The stock has a market capitalization of $40.28 billion, a PE ratio of 26.34, a P/E/G ratio of 3.12 and a beta of 0.76. The company has a quick ratio of 0.80, a current ratio of 1.04 and a debt-to-equity ratio of 1.89.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings results on Tuesday, March 31st. The company reported $0.53 earnings per share for the quarter. Teva Pharmaceutical Industries had a net margin of 9.01% and a return on equity of 44.86%. The firm had revenue of $3.98 billion during the quarter. On average, analysts anticipate that Teva Pharmaceutical Industries will post 2.6 EPS for the current year.

Insider Buying and Selling at Teva Pharmaceutical Industries

In other news, insider Eric A. Hughes sold 9,533 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Thursday, March 5th. The stock was sold at an average price of $31.67, for a total transaction of $301,910.11. Following the sale, the insider owned 107,711 shares of the company’s stock, valued at approximately $3,411,207.37. The trade was a 8.13% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Brian Savage sold 1,127 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Thursday, March 5th. The shares were sold at an average price of $31.67, for a total value of $35,692.09. Following the sale, the insider directly owned 10,914 shares in the company, valued at approximately $345,646.38. This trade represents a 9.36% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 920,901 shares of company stock worth $30,056,789. 0.54% of the stock is owned by company insiders.

Institutional Trading of Teva Pharmaceutical Industries

Institutional investors have recently made changes to their positions in the stock. Aster Capital Management DIFC Ltd acquired a new stake in shares of Teva Pharmaceutical Industries in the 4th quarter worth approximately $25,000. Allworth Financial LP lifted its stake in shares of Teva Pharmaceutical Industries by 53.8% in the 4th quarter. Allworth Financial LP now owns 941 shares of the company’s stock worth $29,000 after acquiring an additional 329 shares during the period. Grove Bank & Trust lifted its stake in shares of Teva Pharmaceutical Industries by 300.0% in the 4th quarter. Grove Bank & Trust now owns 1,000 shares of the company’s stock worth $31,000 after acquiring an additional 750 shares during the period. EverSource Wealth Advisors LLC lifted its stake in shares of Teva Pharmaceutical Industries by 51.8% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,011 shares of the company’s stock worth $32,000 after acquiring an additional 345 shares during the period. Finally, Global Retirement Partners LLC lifted its stake in shares of Teva Pharmaceutical Industries by 27.3% in the 4th quarter. Global Retirement Partners LLC now owns 1,360 shares of the company’s stock worth $42,000 after acquiring an additional 292 shares during the period. 54.05% of the stock is owned by institutional investors and hedge funds.

Key Headlines Impacting Teva Pharmaceutical Industries

Here are the key news stories impacting Teva Pharmaceutical Industries this week:

• Positive Sentiment: Q1 results beat and fundamentals: Teva reported Q1 revenue of ~$4.0B and EPS that topped estimates, driven by branded drugs (Austedo, Ajovy, Uzedy). Management reiterated FY guidance in line with consensus, supporting the near‑term re‑rating thesis. Reuters: Teva beats Q1 profit estimates
• Positive Sentiment: Acquisition expands pipeline: Teva agreed to acquire Emalex (deal reports cite up to ~$900M) to add ecopipam, an NDA‑ready first‑in‑class pediatric Tourette therapy — a strategic, late‑stage asset that supports longer‑term growth. GlobeNewswire: Teva to acquire Emalex
• Positive Sentiment: Multiple analyst upgrades and higher targets: Truist raised its price target to $45 (buy), UBS to $42 (buy), JPMorgan to $40 (overweight), and Piper Sandler reaffirmed overweight at $42 — implying double‑digit upside from current levels and likely supporting buying interest. Benzinga: analyst actions
• Positive Sentiment: Institutional / financing interest: Reports of a $400M Blackstone commitment/financing and unusually large call option activity signal bullish institutional positioning. Fool: Blackstone bet
• Neutral Sentiment: Sustainability milestone: Teva said it met all sustainability‑linked bond targets (~$7.5B of bonds), which reduces ESG-related refinancing risk and links some financial outcomes to ESG KPIs. GlobeNewswire: Healthy Future Report
• Neutral Sentiment: Market research mention: Teva appears in industry reports as a leading player in oral solid dosage CMOs, which is positive for strategic positioning but not an immediate stock catalyst. ResearchAndMarkets / Yahoo
• Negative Sentiment: Generics weakness and near‑term headwinds: Management noted weaker generics revenue (including lenalidomide capsule impacts), a factor that trims margin visibility and may limit near‑term upside despite branded growth. GlobeNewswire: Q1 results

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.